Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer

被引：0
|
作者：
Wu, Z. [1 ]
Pan, H. [2 ]
Ye, M. [3 ]
Chen, L. [4 ]
Qian, W. [4 ]
Zhang, J. [4 ]
机构：
[1] Univ Minnesota, Sci & Engn, Minneapolis, MN 55455 USA
[2] Guangzhou Med Univ, Affiliated Hosp 1, Translat Med, Guangzhou, Guangdong, Peoples R China
[3] Guangzhou Chest Hosp, Internal Med, Guangzhou, Guangdong, Peoples R China
[4] Guangzhou Med Univ, Affiliated Hosp 1, Internal Med, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Apatinib; advance NSCLC; VEGFR-2; inhibitors;
D O I：
10.1016/j.jtho.2018.08.1186
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-131
引用
收藏
页码：S715 / S715
页数：1
相关论文
共 50 条
  • [31] Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications
    Scheffler, Matthias
    Wiesweg, Marcel
    Michels, Sebastian
    Nogova, Lucia
    Kron, Anna
    Herold, Thomas
    Scheel, Andreas H.
    Metzenmacher, Martin
    Eberhardt, Wilfried E.
    Reis, Henning
    Fassunke, Jana
    Darwiche, Kaid
    Aigner, Clemens
    Schaufler, Diana
    Riedel, Richard
    Fischer, Rieke
    Koleczko, Sophia
    Schildhaus, Hans-Ulrich
    Merkelbach-Bruse, Sabine
    Schmid, Kurt W.
    Buettner, Reinhard
    Wolf, Juergen
    Schuler, Martin
    LUNG CANCER, 2022, 168 : 10 - 20
  • [32] Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review
    Wu, Fengying
    Zhan, Shijia
    Gao, Guanghui
    Zhao, Jing
    Ren, Shengxiang
    Zhou, Caicun
    CANCER BIOLOGY & THERAPY, 2018, 19 (03) : 141 - 144
  • [33] Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer
    Huang, Lan
    Li, Li
    Zhou, Yingxu
    Yang, Zhaoyang
    Wang, Meng
    Gao, Yina
    Yang, Yang
    Yang, Fang
    Liu, Bao
    Hong, Xuan
    Chen, Gongyan
    JOURNAL OF CANCER, 2020, 11 (24): : 7137 - 7145
  • [34] Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer
    Bar, Jair
    Ofek, Efrat
    Barshack, Iris
    Gottfried, Teodor
    Zadok, Oranit
    Kamer, Iris
    Urban, Damien
    Perelman, Marina
    Onn, Amir
    LUNG CANCER, 2019, 138 : 109 - 115
  • [35] The Efficiency of Apatinib plus S-1 as Laterline Chemotherapy for Advanced Non-Small-Cell Lung Cancer
    Wu, Z.
    Dai, G.
    Wu, J.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2085 - S2085
  • [36] The Evolution of Therapies in Non-Small Cell Lung Cancer
    Boolell, Vishal
    Alamgeer, Muhammad
    Watkins, David N.
    Ganju, Vinod
    CANCERS, 2015, 7 (03) : 1815 - 1846
  • [37] Biological insights in non-small cell lung cancer
    Rosell, Rafael
    Jain, Anisha
    Codony-Servat, Jordi
    Jantus-Lewintre, Eloisa
    Morrison, Blake
    Ginesta, Jordi Barretina
    Gonzalez-Cao, Maria
    CANCER BIOLOGY & MEDICINE, 2023, 20 (07) : 500 - 518
  • [38] Targeting KRAS in Non-Small Cell Lung Cancer
    Corral de la Fuente, Elena
    Olmedo Garcia, Maria Eugenia
    Gomez Rueda, Ana
    Lage, Yolanda
    Garrido, Pilar
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [39] An alternative synthesis of the non-small cell lung carcinoma drug afatinib
    Kovacevic, Tatjana
    Mesic, Milan
    Avdagic, Amir
    Zegarac, Miroslav
    TETRAHEDRON LETTERS, 2018, 59 (47) : 4180 - 4182
  • [40] Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios
    Tay, Rebecca
    Prelaj, Arsela
    Califano, Raffaele
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1494 - S1502
12345